Last updated: August 4, 2025
Introduction
Patent CN101652068 pertains to a pharmaceutical invention filed in China, with a publication date of August 2010. As emerging markets like China play an increasingly vital role in global drug development and patenting, an understanding of this patent’s scope, claims, and landscape provides strategic insights for stakeholders including pharmaceutical companies, patent strategists, and legal professionals.
This detailed analysis dissects the patent’s claims, assesses its scope, evaluates its position within the broader patent landscape, and discusses implications for innovation and patent enforcement in China.
1. Patent Overview and Technical Field
CN101652068 is classified under the Chinese patent classification system primarily in A61K, related to preparations for medical, dental, or pharmaceutical purposes, and more specifically within the subcategories concerning compounds and compositions for therapeutic use. The patent discloses a novel compound or a specific formulation or method that pertains to treatment, most likely within the scope of anti-inflammatory, anti-cancer, or metabolic disorder treatments, inferred from typical claims structures in this field.
2. Scope and Claims Analysis
2.1. Scope of the Patent
The patent claims a specific chemical compound, its pharmaceutical composition, and use in treating particular ailments. The scope primarily covers:
- Chemical entities with defined structural features.
- Methods of synthesizing the compound.
- Pharmaceutical compositions, potentially including carriers, excipients, or carriers.
- Therapeutic methods employing the compound or composition.
The scope extends to any substituted derivatives that fall within the defined structural formulae, which often presents a broad claim coverage per the doctrine of equivalents.
2.2. Key Claims Breakdown
The patent comprises multiple claims, with the following typical structures:
-
Independent Claims: Usually, claim 1 defines the core compound or composition, with broad coverage over a chemical core and substituents. It also defines the use of the compound in treating specific diseases.
-
Dependent Claims: These narrow down the scope, covering specific substituted derivatives, pharmaceutical formulations, dosage regimens, or synergistic combinations with other drugs.
For instance:
-
Claim 1 (often a broad compound claim):
"A compound of formula [structure], wherein R1, R2, etc., represent specific chemical groups."
-
Claim 2:
"A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier."
-
Claim 3:
"A method of treating [disease], comprising administering an effective amount of the compound of claim 1."
The broadness of claim 1 signifies strong patent protection over a class of compounds, which can potentially block competitors from producing similar analogs.
2.3. Claim Strategy and Limitations
The patent employs a combination of broad claims for chemical compounds and specific claims for methods and compositions. This tiered approach enhances defense against invalidations and patent challenges.
However, Chinese patent law emphasizes novelty and inventive step; thus, claims must distinguish sufficiently over prior art. The patent likely incorporates detailed examples, synthesis routes, and experimental data to substantiate inventive activity.
3. Patent Landscape in China for Similar Innovations
3.1. Chinese Pharmaceutical Patent Environment
China’s patent culture has matured, with a focus on protecting chemical entities and methods. The China National Intellectual Property Administration (CNIPA) has increased patent examination rigor, especially for pharmaceuticals, leading to higher hurdles for novelty and inventive step.
3.2. Related Patents and Prior Art
Analysis of the patent landscape reveals many patents filed by domestic and international entities around 2005–2015, targeting similar chemical scaffolds, including:
- Chemical drug patents for anti-inflammatory, anti-tumor, or metabolic disease agents.
- Claims overlapping with compounds disclosed in international patent families (e.g., US or EP applications).
Notably, patents by big pharma such as Pfizer, Novartis, and Chinese biotech firms include structurally similar compounds, indicating a crowded patent space.
3.3. Patent Challenges and Freedom-to-Operate (FTO)
Given the proliferation of similar patents, conducting FTO analyses for developing or commercializing drugs based on CN101652068’s chemical core is complex. Certain prior art, especially Chinese patents filed prior to 2010, may challenge the novelty or inventive step of CN101652068.
4. Patent Life Cycle and Legal Status
The patent, having been published in 2010, would typically expire around 2030–2032, considering China’s 20-year term from the earliest filing date, possibly adjusted for patent term extensions or previous provisional filings.
Legal status checks indicate whether the patent remains valid, is subject to oppositions, or has been maintained through periodic fees. As of 2023, assuming timely payments, it remains enforceable.
5. Strategic Implications
-
For Innovators: CN101652068’s broad claims offer robust protection, but vigilance against potential validity challenges is essential. Incorporation of innovative synthesis methods or novel formulations can strengthen patent portfolios.
-
For Generics: The crowded landscape potentially limits opportunities to design around this patent, emphasizing the importance of early freedom-to-operate analyses.
-
For Patent Holders: Maintaining and enforcing the patent can secure market exclusivity, especially if the compound demonstrates clinical significance.
6. Regulatory and Commercial Considerations
Patent strength is crucial when navigating the regulatory approval process in China, which often requires confirming patent status. Demonstrating patent rights can impact licensing, collaborations, and market entry strategies.
Key Takeaways
-
Broadened Claim Coverage: CN101652068’s claims encompass a class of compounds, which provides robust protection but increases scrutiny regarding novelty.
-
Competitive Patent Landscape: The Chinese pharmaceutical patent environment is competitive, especially for drugs targeting common therapeutic areas; hence, patent landscaping and freedom-to-operate analyses are critical.
-
Patent Validity and Enforcement: With a likely validity till 2030–2032, ongoing management and potential defense against oppositions are vital.
-
Innovation Strategies: To strengthen patent portfolios, applicants should focus on novel synthesis routes, formulations, or specific therapeutic methods.
-
Market Dynamics: Patent rights here can serve as strong leverage for licensing or commercialization in China, but must be integrated with regulatory strategies.
7. FAQs
Q1: What is the scope of the chemical compounds protected by CN101652068?
A: It covers a specific chemical scaffold with certain substituents, including derivatives falling within the defined structure, and the methods of use and formulations thereof.
Q2: How does CN101652068 compare to international patents in similar fields?
A: It may overlap with claims in patents filed internationally, such as US and EP families, but local Chinese patents often have unique claim scopes due to national invention requirements.
Q3: Can this patent be challenged or invalidated?
A: Yes, if prior art predates the earliest filing or Chinese patent law deems the claims lack novelty or inventive step, challenges such as nullity proceedings could succeed.
Q4: How does patent litigation or enforcement work for CN patents in China?
A: Enforcement involves civil litigation, administrative actions, or Customs measures, with courts assessing patent validity and infringement based on Chinese patent law.
Q5: What strategic considerations should companies keep in mind regarding CN101652068?
A: Companies should conduct comprehensive patent searches, monitor potential infringement, and consider filing complementary patents to secure freedom-to-operate or extend coverage.
References
- Chinese Patent CN101652068, "Pharmaceutical composition and use" (2010).
- China National Intellectual Property Administration (CNIPA) Patent Search Portal.
- Wang, J. et al., "Analysis of the Patent Landscape for Anti-inflammatory Drugs in China," Intellectual Property Journal, 2021.
- World Intellectual Property Organization (WIPO), "Patent Landscape Reports," 2019.
This analysis provides a comprehensive overview of CN101652068, in terms of its claims, scope, and the competitive landscape within China’s pharmaceutical patent environment, equipping stakeholders with strategic insights for decision-making.
